Alveo Technologies Announces Open Platform Strategy. Click
here to read the news.
Nov 17, 2022
Molecular Sensing and Diagnostics Leader Enters European Market with Novel Point-of-Care Infectious Disease Diagnostic Platform, Seeks Development and Commercialization Partners Alameda, CA – November 17, 2022 – Alveo Technologies, Inc. (Alveo) today announced the...
Mar 16, 2021
Prestigious honor validates potential of Alveo’s low-cost, accessible COVID-19 testing technology as company prepares for commercialization Click to watch how the be.well™ COVID-19 Test works. Alameda, Calif. – March 17, 2021 – Alveo Technologies, Inc. (Alveo)...
Nov 2, 2020
Infectious Disease Diagnostic Innovator Receives Grant from the Bill & Melinda Gates Foundation to Advance Accessibility and Commercialization for At-Home COVID-19 Testing Alameda, CA – 11/2/20 – Alveo Technologies, today announced it has been awarded a grant to...
Apr 30, 2020
Alameda, CA – April 30, 2020 – Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen...
Feb 20, 2020
We are thrilled to announce today that in February 2020 Alveo Technologies was presented with a Food and Drug Branch License (FDB License) after an in-person inspection by a Food and Drug Investigator from the State of California Food and Drug Branch of the Food and...
Jan 5, 2018
SAN FRANCISCO – Jan 5, 2018 – Alveo Technologies, Inc., (“Alveo” or “the Company”) whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised...
